Commonwealth Equity Services Inc increased its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.8% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 33,552 shares of the medical equipment provider’s stock after purchasing an additional 914 shares during the period. Commonwealth Equity Services Inc’s holdings in Zimmer Biomet Holdings were worth $3,928,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in ZBH. Enterprise Financial Services Corp raised its holdings in shares of Zimmer Biomet Holdings by 0.3% in the 2nd quarter. Enterprise Financial Services Corp now owns 2,646 shares of the medical equipment provider’s stock valued at $340,000 after purchasing an additional 9 shares in the last quarter. Parkside Financial Bank & Trust boosted its holdings in shares of Zimmer Biomet Holdings by 3.9% in the second quarter. Parkside Financial Bank & Trust now owns 872 shares of the medical equipment provider’s stock valued at $112,000 after acquiring an additional 33 shares in the last quarter. CWA Asset Management Group LLC boosted its holdings in shares of Zimmer Biomet Holdings by 1.8% in the second quarter. CWA Asset Management Group LLC now owns 1,952 shares of the medical equipment provider’s stock valued at $251,000 after acquiring an additional 34 shares in the last quarter. Advisory Services Network LLC boosted its holdings in shares of Zimmer Biomet Holdings by 1.0% in the second quarter. Advisory Services Network LLC now owns 3,690 shares of the medical equipment provider’s stock valued at $474,000 after acquiring an additional 37 shares in the last quarter. Finally, Palladium Partners LLC boosted its holdings in shares of Zimmer Biomet Holdings by 1.7% in the second quarter. Palladium Partners LLC now owns 2,501 shares of the medical equipment provider’s stock valued at $321,000 after acquiring an additional 41 shares in the last quarter. Institutional investors own 85.36% of the company’s stock.

WARNING: “Zimmer Biomet Holdings, Inc. (ZBH) Shares Bought by Commonwealth Equity Services Inc” was first reported by Watch List News and is the property of of Watch List News. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/zimmer-biomet-holdings-inc-zbh-shares-bought-by-commonwealth-equity-services-inc/1717771.html.

Zimmer Biomet Holdings, Inc. (ZBH) traded up $0.57 during midday trading on Tuesday, hitting $112.18. 939,000 shares of the stock were exchanged, compared to its average volume of 1,362,769. The company has a quick ratio of 0.78, a current ratio of 1.47 and a debt-to-equity ratio of 0.88. The stock has a market capitalization of $22,640.00, a price-to-earnings ratio of 13.83, a price-to-earnings-growth ratio of 1.73 and a beta of 1.17. Zimmer Biomet Holdings, Inc. has a 1-year low of $98.20 and a 1-year high of $133.49.

Zimmer Biomet Holdings (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.74 by ($0.02). The business had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.83 billion. Zimmer Biomet Holdings had a net margin of 8.36% and a return on equity of 16.29%. Zimmer Biomet Holdings’s revenue was down .8% compared to the same quarter last year. During the same period in the previous year, the business posted $1.79 EPS. equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.03 EPS for the current fiscal year.

A number of research firms have recently weighed in on ZBH. Zacks Investment Research lowered shares of Zimmer Biomet Holdings from a “hold” rating to a “strong sell” rating in a research report on Monday. Deutsche Bank AG upgraded shares of Zimmer Biomet Holdings from a “hold” rating to a “buy” rating and set a $128.00 price objective for the company in a research note on Tuesday, November 14th. Edward Jones upgraded shares of Zimmer Biomet Holdings from a “hold” rating to a “buy” rating in a research note on Thursday, November 9th. Royal Bank Of Canada reduced their price objective on shares of Zimmer Biomet Holdings to $125.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 7th. Finally, Stifel Nicolaus reiterated a “hold” rating and set a $120.00 price objective on shares of Zimmer Biomet Holdings in a research note on Friday, November 3rd. Four analysts have rated the stock with a sell rating, seven have given a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $133.71.

Zimmer Biomet Holdings Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.